IMVT241115C17000
- 0.00
- 0.000.00%
Immunovant Newsroom
H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $48 to $58
Immunovant's Promising Pipeline and Strategic Advancements Justify Buy Rating
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
Promising Phase 2a Results for Immunovant's Batoclimab Support Buy Rating
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
Raymond James Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $36
Immunovant Is Maintained at Outperform by Oppenheimer
Immunovant Analyst Ratings
Oppenheimer Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $53
H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $57
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $44 to $60
Buy Rating Affirmed for Immunovant Amid Promising IMVT-1402 Clinical Trial Results for Graves' Disease
Immunovant Analyst Ratings
LifeSci Capital Sticks to Its Buy Rating for Immunovant (IMVT)
BofA Securities Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $49
Immunovant's IMVT-1401: A High Potential Buy Rating for Unmet Graves' Disease Needs
Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $57